Hereditary Ovarian Cancer — approximately 20-25% of ovarian cancers have hereditary causes, the highest proportion of any common cancer, and PARP inhibitors have transformed outcomes for BRCA-positive patients.
Whole genome sequencing evaluates all ovarian cancer predisposition genes — BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, MLH1, MSH2, MSH6, PALB2 — providing comprehensive genetic assessment for treatment selection and family cancer prevention.
Ovarian Cancer — Hereditary
Ovarian cancer has the highest hereditary fraction of any common cancer — approximately 20-25% of epithelial ovarian cancers (EOC) have identifiable germline pathogenic variants. BRCA1 (~39-46% lifetime ovarian cancer risk) and BRCA2 (~11-18% lifetime risk) are the most common, accounting for approximately 15% of all EOC. Additional genes include RAD51C (~5-10% lifetime risk), RAD51D (~5-13% lifetime risk), BRIP1 (~5-6% lifetime risk), and Lynch syndrome genes MLH1/MSH2/MSH6 (3-14% lifetime risk, particularly endometrioid and clear cell subtypes). Emerging evidence supports PALB2 as a moderate ovarian cancer risk gene.
PARP inhibitors have transformed hereditary ovarian cancer treatment. Olaparib, niraparib, and rucaparib are FDA-approved for BRCA-mutated ovarian cancer in various settings (maintenance after platinum chemotherapy, recurrent disease). The SOLO-1 trial demonstrated that olaparib maintenance after first-line platinum chemotherapy in germline BRCA-mutated advanced ovarian cancer reduced the risk of progression by 70% — a paradigm-shifting result. RAD51C and RAD51D variants also confer homologous recombination deficiency (HRD) and sensitivity to PARP inhibitors, though specific approvals for these genes are evolving.
Risk-reducing salpingo-oophorectomy (RRSO) is the most effective prevention strategy for hereditary ovarian cancer. RRSO reduces ovarian cancer risk by approximately 80% in BRCA1/2 carriers and is recommended between ages 35-40 for BRCA1 and 40-45 for BRCA2 — after completion of childbearing. Currently, no effective ovarian cancer screening strategy exists for the general population (CA-125 and transvaginal ultrasound have insufficient sensitivity/specificity for population screening). This makes genetic identification of high-risk individuals particularly critical — RRSO is the primary prevention tool, and it requires knowing who should receive it.
There is NO effective population screening for ovarian cancer. Unlike breast cancer (mammography) and colon cancer (colonoscopy), ovarian cancer prevention relies on identifying genetic high-risk individuals and offering risk-reducing surgery. Genetic testing is the prevention strategy.
Ovarian cancer prevention depends on genetic identification — there is no effective screening test. RRSO reduces risk by ~80% but requires knowing who carries a high-risk variant. Genetic testing IS the prevention program.
PARP inhibitor eligibility requires germline BRCA confirmation — and RAD51C/D are emerging as additional PARP-sensitive genes
PARP inhibitor maintenance after platinum chemotherapy has become standard of care for germline BRCA-mutated ovarian cancer based on landmark trials (SOLO-1, PRIMA, ARIEL3). Germline testing is now recommended for ALL ovarian cancer patients at diagnosis — not just those with family history — because 15-20% will carry actionable variants. RAD51C and RAD51D variants also confer HRD and emerging evidence supports PARP inhibitor sensitivity. WGS evaluates all HRD genes simultaneously.
BRCA1 vs. BRCA2 have different optimal RRSO timing — molecular identification of the specific gene determines the surgical window
BRCA1 carries higher ovarian cancer risk with earlier median onset — RRSO is recommended by age 35-40. BRCA2 carries lower risk with later onset — RRSO can be deferred to 40-45, preserving natural menopause and cardiovascular/bone health longer. For RAD51C and RAD51D, RRSO timing recommendations are still being refined but generally align with BRCA2 timing. Without molecular identification of the specific gene, RRSO timing cannot be optimized.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for Ovarian Cancer — Hereditary and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
